Interdicting $G_q$ activation in airway disease by receptor-dependent and receptor-independent mechanisms*

Richard Carr III, Cynthia Koziol-White, Jie Zhang, Hong Lam, Steven S. An, Gregory G. Tall, Reynolds A. Panettieri, Jr., and Jeffrey L. Benovic

Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, RC III, JLB
Department of Medicine, Pulmonary, Allergy and Critical Care Division, Airways Biology Initiative, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, CKW, JZ, RAP Jr.
Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, HL, SSA
Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY 14642, GGT
Running title: Interdicting G_q activation in airway disease

Correspondence: Jeffrey L. Benovic, Ph.D.,
Department of Biochemistry and Molecular Biology
Thomas Jefferson University
233 S. 10th St., 926 BLSB
Philadelphia, PA 19107
Tel.: 215-503-4607
E-mail: jeffrey.benovic@jefferson.edu

Number of text pages: 35

Number of tables: 0

Number of figures: 4

Number of words in Abstract: 221

Number of words in Introduction: 525

Number of words in Discussion: 1498

Abbreviations: β2AR, β2-adrenergic receptor; ASM, airway smooth muscle; cAMP, 3’-5’-cyclic adenosine monophosphate; CXCR, CXC chemokine receptor; DPBS, Delbecco’s phosphate buffered saline; EC_{50}, half maximal effective concentration; fsk, forskolin; DTT, dithiothreitol; G_{12/13}, G_{α12/13}βγ heterotrimer; G_i, G_{αi}βγ heterotrimer; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; G_s, G_{αs}βγ heterotrimer; GST, glutathione S-transferase; G_q, G_{αq}βγ heterotrimer; GTPγS, guanosine 5’-O-[gamma-thio]triphosphate; IBMX, 3-isobutyl-1-methylxanthine; IC_{50}, half maximal inhibitory concentration; iso, isoproterenol; PAR, protease activated receptor; PCLS, precision cut lung slice; PI3K, phosphatidylinositol-3-kinase; PDK1, phosphoinositide-dependent kinase-1; PTX, pertussis toxin; RBD, Rhotekin Rho binding domain; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TXA_2R, thromboxane A2 receptor
Abstract

Gq, an important mediator in the pathology of airway disease, plays a central role in bronchoconstriction and airway remodeling including airway smooth muscle (ASM) growth and inflammation. Current therapeutic strategies to treat airway disease include the use of muscarinic and leukotriene receptor antagonists; however, these pharmaceuticals demonstrate a limited clinical efficacy as multiple Gq-coupled receptor subtypes contribute to these pathologies. Thus, broadly inhibiting the activation of Gq may be an advantageous therapeutic approach. Here, we investigated the effects of broadly inhibiting Gq activation in vitro and ex vivo using receptor-dependent and receptor-independent strategies. P4pal-10 is a PAR4-derived pepducin that exhibits efficacy towards multiple Gq-coupled receptors. Mechanistic studies demonstrated that P4pal-10 selectively inhibits all G protein coupling to several Gq-coupled receptors including PAR1, muscarinic acetylcholine M3 and histamine H1 receptors while demonstrating no direct effect on Gq. We also evaluated the ability of FR900359, also known as UBO-QIC, to directly inhibit Gq activation. FR900359 inhibited spontaneous Gαq nucleotide exchange while having little effect on Gs, Gi or G12/13 activity. Both P4pal-10 and FR900359 inhibited Gq-mediated intracellular signaling and primary human ASM growth while only FR900359 effectively interdicted agonist-promoted airway contraction in human precision cut lung slices. These studies serve as proof-of-concept that the broad-based inhibition of Gq activation may be a useful therapeutic approach to treat multiple common pathologies of airway disease.
Introduction

Asthma manifests as a complex respiratory syndrome of airway hyperresponsiveness and inflammation. Airway smooth muscle (ASM) shortening evokes airway obstruction that clinically manifests as a significant decrease in peak airflow (Deshpande and Penn, 2006). Common therapeutic interventions include the use of glucocorticoids to curb airway inflammation and are often combined with a long-acting β-agonist. Other therapies include leukotriene and muscarinic receptor antagonists that inhibit the activation of Gq-coupled receptors that mediate parasympathetic and hormonal signaling regulating bronchomotor tone (Bel, 2013). GPCR antagonists have somewhat limited efficacy in patients as the activation of multiple Gq-coupled receptors contribute to the pathology of the disease (Moulton and Fryer, 2011; Scadding and Scadding, 2010). It is plausible that inhibiting Gq activation at the receptor or the G protein level would be an advantageous asthma therapeutic as Gq-mediated ASM shortening is a primary contributor to bronchotone (Borchers et al., 2003; Pelaia et al., 2008).

P4pal-10 is a pepducin antagonist derived from intracellular loop 3 of protease-activated receptor 4 (PAR4) (Covic et al., 2002). In the initial report, P4pal-10 demonstrated efficacy in preventing PAR4-mediated platelet activation ex vivo and exhibited anti-thrombotic activities in vivo. Interestingly, P4pal-10 inhibited both PAR1- and PAR4-mediated platelet aggregation and it was suggested this was due to disruption of the activity of PAR1/PAR4 heterodimers and loss of responsiveness from both receptor subtypes. Moreover, while Covic et al. reported that P4pal-10 had little effect on thromboxane A2 receptor (TXA2R) function in platelets (Covic et al., 2002), other investigators reported that TXA2R was sensitive to P4pal-10 in human platelet aggregation at concentrations comparable to those used to inhibit PAR1 and PAR4 (Stampfuss et al., 2003). Here, we further investigated the putative multiple efficacies of P4pal-10 and applied
its unique properties to understand mechanisms and application of broad-based $G_q$ inhibition in the treatment of airway disease.

The relative therapeutic advantage of broad-based $G_q$ inhibition was also studied using a small molecule inhibitor of $G_q$ activation, FR900359 (also known as UBO-QIC). FR900359 is a cyclic depsipeptide isolated from the roots of *Ardisia crenatasim* that is nearly structurally identical to the well-studied $G_q$ inhibitor YM-254890 (Fujioka et al., 1988; Taniguchi et al., 2003, Takasaki et al., 2004; Bernard et al., 2014). Although not as well-characterized as YM-254890, FR900359 likely retains the same properties and mode of operation. Structural studies of a YM-254890/$G_\alpha_q$ complex revealed that the compound interacts with the hinge region between the $\alpha$-helical domain and GTPase domain of $G_\alpha_q$ (Nishimura et al., 2010). These contacts may inhibit the opening of the nucleotide binding pocket that is requisite for GDP/GTP exchange and subsequent G protein activation. Recent studies using FR900359 demonstrate efficacy in inhibiting $G_q$-mediated signaling in human platelets with little effect on the activity of $G_s$, $G_i$ or $G_{12/13}$ (Inamdar et al., 2015). Further, the proposed vasorelaxant properties were confirmed in an *ex vivo* model of rat aortic relaxation (Zaima et al., 2013). FR900359 has also been used as a molecular tool to dissect cellular signaling pathways that include the influence of $G_\beta\gamma$-RGS7 complex formation on $G_q$-mediated calcium flux (Karpinsky-Semper et al., 2014). Here, we assessed the ability of FR900359 to inhibit $G_q$-dependent airway smooth muscle growth and airway contraction.

**Materials and Methods**

**Materials** - P4pal-10 (palmitate-SGRRYGHALR-amide), scrambled P4pal-10 (P4pal-10 Scr, palmitate-YLHARGSRGR-amide) and PAR1-agonist peptide (PAR1-AP, SFLLRN) were
synthesized by an Fmoc solid-phase protocol and purified to >98% by C18 reverse-phase chromatography (Peptide2.0). FR900359 was acquired under the name of UBO-QIC from the Pharmazeutische Biologie at the Universität Bonn. Pertussis toxin from Bordetella pertussis, adenosine 5′-triphosphate disodium salt hydrate (99%), bradykinin (RPPGFSPFR) acetate salt (99%), forskolin from Coleus forskohlii (≥ 98%), (-)-isoproterenol hydrochloride (≥ 98%) and histamine (≥ 97%) were purchased from Sigma-Aldrich. Carbamylcholine chloride (carbachol, 99%) was purchased from Acros Organics. Purified recombinant human SDF-1α was obtained from ProSpec.

**Cell Culture**- HEK293 and HeLa cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Cellgro) supplemented with 10% fetal bovine serum (FBS). Primary human airway smooth muscle cells were isolated from donors with no known chronic illness or medication use as previously described (Panettieri et al., 1989). Passages 4 to 7 ASM cells were maintained in complete medium (Ham's F-12 medium supplemented with 10% FBS, 25 mM HEPES, pH 7.2, 1.7 mM CaCl2, 2 mM L-glutamine, 0.2 units/ml of penicillin, and 100 μg/ml streptomycin). The use of human ASM cells does not constitute human subjects research as all donor tissue is harvested anonymously and de-identified. All cells were maintained at 37 °C in a humidified 5% CO2 incubator. Cells were untransfected unless specifically noted.

**Calcium Mobilization**- Calcium mobilization was performed as previously described with slight modifications (Luo et al., 2008). HEK293 cells or primary human ASM cells were grown to confluence in 15 cm dishes. Cells were treated with CellStripper (CellGro), washed and concentrated to 5x10^6 cells/mL in Hank’s Balanced Salt Solution (HBSS, CellGro) with 0.025% BSA. Fura2-AM (Life Technologies) dye was added to 2 μM, gently rocked and incubated for 45 min at 37 °C. Cells were pelleted by centrifugation and the supernatant was replaced with 5 mL
of HBSS and incubated at room temperature for 15 min to allow Fura2-AM processing. Cells were pelleted by centrifugation, washed and resuspended at 30x10⁶ cells/mL in ice-cold HBSS with 0.025% BSA. To measure calcium mobilization, 50,000 cells were incubated in HBSS without calcium and magnesium (Cellgro) with 0.025% BSA in the presence or absence of various concentrations of P4pal-10 for 1 min at 37 °C. Cells treated with FR900359 were incubated on ice for 10 min before addition to the assay cuvette and 1 min incubation at 37 °C before addition of agonists (final concentrations: 100 μM PAR1-AP, 100 μM carbachol, 100 nM bradykinin, 100 μM histamine, 10 μM ATP; concentrations that promoted maximal calcium mobilization were used). Fura2-AM fluorescence was monitored using excitation at 340 and 380 nm and emission at 510 nm over a time course (LS55; PerkinElmer). Percent responsiveness was calculated as the fraction of peak response of the inhibitor treated cells as compared to the response of the cognate ligand using cells not treated with inhibitor.

**Gₘ activation** - HEK293 cells were plated in 24-well plates and grown to confluence in complete media. Before assaying, cells were treated with DMSO (0.5%), 100 nM FR900359, 10 μM P4pal-10 or 10 μM P4pal-10 Scr for 10 min at 37 °C. Cells were stimulated with 100 nM isoproterenol for 10 min in the presence of 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma-Aldrich). Cells were lysed by the addition of 80 μL 0.1 M HCl followed by a 20 min incubation on an orbital shaker at room temperature. Lysates were cleared by centrifugation at 1,000 x g for 10 min. cAMP levels were measured using the Cayman Chemical Cyclic AMP EIA kit following the manufacturer’s instructions. Responsiveness was calculated as a percent of isoproterenol-promoted cAMP produced as compared to the DMSO-treated cells.

**Gₐ activation** - HEK293 cells were plated in 24-well plates and grown to confluence in complete media. Before assaying, cells were treated with DMSO (0.5%), 100 nM FR900359, 10
μM P4pal-10 or 10 μM P4pal-10 Scr for 10 min at 37 °C. In pertussis toxin treated samples, cells were preincubated overnight with 100 ng/ml pertussis toxin at 37 °C. Cells were treated for 1 min with agonist (50 nM SDF-1α for CXCR4 experiments; 100 μM PAR1-AP for PAR1 experiments) before stimulation with 10 μM forskolin for 10 min. cAMP production was measured as described above. Responsiveness was calculated as a percent of forskolin-promoted cAMP produced as compared to the DMSO-treated cells.

**Gaₐq purification**- Rat Gaₐq and Glutathione-S-Transferase (GST)-tagged Ric-8A were co-expressed from amplified, recombinant baculoviruses (2 ml and 8 ml, respectively) in 1L of High-Five (Invitrogen) insect cell suspension culture for 48 h. Insect cells were harvested and lysed in 20 mM HEPES, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM dithiothreitol (DTT), 11 mM CHAPS, 1 μM GDP, and protease inhibitor mixtures, as described (Chan et al., 2011a). GST-Ric-8A:Gaₐq complexes were captured from the clarified lysates with glutathione Sepharose 4B (GE Healthcare). The column was washed and Gaₐq was eluted slowly at 22 °C with 20 mM HEPES, pH 8.0, 50 mM MgCl₂, 1 mM DTT, 11 mM CHAPS, 100 μM GDP, 10 mM NaF, 30 μM AlCl₃, and protease inhibitor mixtures. The Gaₐq was loaded onto a 1 ml Hi-Trap Q column (GE Healthcare) that had been equilibrated with 20 mM HEPES, pH 8.0, 1 mM EDTA, 1 mM DTT, 11 mM CHAPS, and eluted with a linear gradient to 500 mM NaCl in the same buffer. The Gaₐq Hi-Trap Q pool was concentrated using an Amicon Ultra-15 30,000 MWCO ultracentrifugal device and gel filtered over a Superdex 200 HR10/300 column in 20 mM HEPES, pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 11 mM CHAPS, 1 μM GDP. The Gaₐq was evaluated for purity by Coomassie-stained SDS-PAGE and for activity using a Ric-8A-stimulated [³⁵S]-GTPγS binding assay (Chan et al., 2011b).
**Spontaneous GTPγS binding** - Intrinsic Gαq GTPγS binding measurements were performed as described (Nishimura et al., 2010). In brief, purified Gαq (500 nM) was preincubated with DMSO (0.5%), P4pal-10 or FR900359 for 5 min at 20°C in assay buffer (50 mM HEPES, pH 7.5, 1 mM EDTA, 1 mM DTT, 0.9 mM MgSO₄, and 0.05% Lubrol). Reactions were initiated by the addition of 10 μM [³⁵S]-GTPγS (Perkin Elmer) and 300 mM (NH₄)₂SO₄. The reactions were stopped by the addition of 4 mL of ice-cold wash buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 2 mM MgSO₄) and the Gαq was captured by rapid filtration through BA85 nitrocellulose membranes (Millipore). The membranes were washed four times with 4 mL of ice-cold wash buffer and [³⁵S]-GTPγS binding was quantitated by liquid scintillation counting.

**Detection of active RhoA** - Glutathione S-Transferase-Rhotekin Rho Binding Domain (GST-RBD, a generous gift from Dr. Philip Wedegaertner, Thomas Jefferson University) was expressed in E. Coli BL21 cells grown at 37 °C in 100 μg/mL ampicillin until an optical density reading at 600 nm was approximately 0.6 AU. Protein expression was induced by the addition of 0.5 mM (final concentration) isopropyl β-D-1-thiogalactopyranoside (IPTG) and continued for 3 hr at 30 °C. Cells were pelleted by centrifugation at 5000 x g for 15 min at 4 °C and resuspended in 10 mL of STE buffer (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA and 1 Complete protease inhibitor tablet (Roche)). 100 μL of 1 M DTT and 1.4 mL of 10% Sarkosyl were added and mixed by inversion. The resuspension was sonicated for 1 min and centrifuged at 18,000 x g for 30 min at 4 °C. 4 mL of 10% Triton X-100 was added to the supernatant and the solubilized mixture was supplemented with STE buffer to 20 mL. 1 mL of Glutathione Sepharose beads, pre-equilibrated with Delbecco’s phosphate buffered saline (DPBS), was added to the cleared lysate. GST-RBD loading occurred over a 1 hr incubation at room temperature with gentle
rocking. Glutathione Sepharose beads were pelleted and washed 3 times with 50 mL of DPBS. Washed beads were suspended in DPBS, snap-frozen and stored at -80 °C.

HeLa cells were grown in 6-well plates to 60% confluency and transfected with FLAG-PAR1 for 48 hr prior to experiment using X-tremeGENE 9. Transfected HeLa cells were washed with DPBS and serum starved in DMEM for 4 hr at 37 °C. 10 min before stimulation, 10 μM P4pal-10, 100 nM FR900359 or 0.5% DMSO was added to the appropriate wells. After incubation, cells were stimulated with 100 μM PAR1-AP for 5 min at 37 °C. On ice, stimulation media was removed and cells were lysed with 200 μL of lysis buffer (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholate, 1% Triton X-100, 20 mM MgCl₂ and 1 complete mini protease inhibitor tablet (Roche)). Cells were scraped, briefly sonicated on ice, and centrifuged at 1,000 x g for 10 min at 4 °C. 5 μL of each lysate was saved for total RhoA analysis. Equal protein from each lysate was incubated with 40 μg of GST-RBD for 1 hr at 4 °C. The beads were pelleted by centrifugation and washed twice with buffer (25 mM Tris-HCl, pH 7.5, 40 mM NaCl, 30 mM MgCl₂ and 1 complete mini protease inhibitor tablet). Bound RhoA was eluted with 2x Laemelli buffer. Proteins were separated by SDS-PAGE on a 10% polyacrylamide gel and activated RhoA pull-down was analyzed by western blotting. RhoA was detected using a monoclonal RhoA antibody (1:1000, Santa Cruz Biotechnologies) in Tris buffered saline with Tween-20 (20 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.1% Tween-20) (TBST) plus 5% BSA. Equal protein loading and RhoA expression was confirmed by blotting for RhoA after SDS-PAGE analysis of the initial lysates. For detection, western blots were incubated for 1 h at room temperature with goat anti-mouse IRDye 800 conjugated (LI-Cor Biosciences) antibodies at 1:2000. Detection of fluorescence was performed using an ODYSSEY infrared imaging system (LI-Cor Biosciences).
**Airway smooth muscle growth** - Primary human airway smooth muscle cells were plated at a density of 10,000 cells per well on a 96-well white opaque plate pre-coated with poly-L-lysine in complete media. After 24 hr, the complete media was removed and the cells were washed once with DPBS. Each well was supplemented with 100 μL of media (Ham's F12 medium, 25 mM HEPES, 1.7 mM CaCl₂, 2 mM L-Glutamine, 0.2 units/ml of penicillin, 100 μg/ml streptomycin, 5 μg/mL apo-transferrin, 1 μM insulin and 100 μM ascorbic acid) and incubated for 48 hr at 37 °C. The media was removed and cells were incubated with DMSO (0.5%), 10 μM P4pal-10, or 100 nM FR900359 for 30 min in serum-free ASM media (Ham's F12 medium, 25 mM HEPES, 1.7 mM CaCl₂, 2 mM L-Glutamine, 0.2 units/ml of penicillin, and 100 μg/ml streptomycin). At 30 min, cells were treated with vehicle (serum-free ASM media), 1 U/mL thrombin, 10 nM epidermal growth factor (EGF, Sigma-Aldrich), or a thrombin/EGF combination for 24 hr. Media was then removed and each well was incubated with 100 μL of WFI water (Cellgro) for 1 hr at 37 °C. 100 μL of 2x Pico Green Mix (Invitrogen) was added to each well and cells were incubated in the dark for 1 hr at room temperature. Pico Green fluorescence was excited at 485 ± 20 nm and emission was monitored at 515 ± 25 nm on a Tecan Infinite F500 microplate reader.

**AKT phosphorylation** - Primary human ASM cells were grown to 70-80% confluence in 6-well plates in complete media. Cells were starved for 24 hr in serum free media. 10 min prior to stimulation, cells were treated with DMSO (0.5%), 10 μM P4pal-10, or 100 nM FR900359. Cells were stimulated with vehicle (serum-free ASM media), 1 U/mL thrombin, 10 nM EGF or a thrombin/EGF combination for 6 hr at 37 °C. On ice, cells were lysed by the addition of 200 μL of lysis buffer (20 mM HEPES, pH 7.2, 150 mM NaCl, 10 mM EDTA, 1% Triton X-100 and 1 Complete protease inhibitor tablet) and brief sonication. 5x Laemelli buffer was added and
samples were boiled for 5 min. Samples were separated by SDS-PAGE on a 10% polyacrylamide gel and AKT phosphorylation was analyzed by western blotting. AKT phosphorylation was detected using a phosphospecific antibody (1:1000) against AKT phosphoserine 473 (pS\(^{473}\), Cell Signaling Technology) in TBST with 5% BSA. Equal AKT expression was confirmed by stripping the blot and reprobing using rabbit polyclonal anti-AKT (Cell Signaling Technology), at 1:1000 in TBST with 5% BSA. For detection, western blots were incubated for 1 h at room temperature with both goat anti-rabbit IRDye 680 conjugated (LI-Cor Biosciences) and goat anti-mouse IRDye 800 conjugated (LI-Cor Biosciences) antibodies at 1:2000. Detection of fluorescence was performed using an ODYSSEY infrared imaging system (LI-Cor Biosciences).

**Preparation of precision cut lung slices**- Human precision cut lung slices (PCLS) were prepared from donor lungs unsuitable for transplantation in accordance with the Institutional Review Board at the University of Pennsylvania as previously described (Cooper and Panettieri, 2008; Cooper et al., 2011). Briefly, whole human lungs from non-asthma donors with no known chronic illness or medication use were dissected and inflated using 2% (wt/vol) low melting point agarose. Once the agarose set, the lobe was sectioned, and cores of 8-mm diameter were made. The cores that contained a small airway by visual inspection were sliced at a thickness of 350 \(\mu\)m (Precisionary Instruments VF300 Vibratome, Greenville, NC) and collected in wells containing supplemented Ham's F-12 medium. Suitable airways (\(\leq\)1-mm diameter) on slices were selected on the basis of the following criteria: presence of a full smooth muscle wall, presence of beating cilia, and unshared muscle walls at airway branch points to eliminate possible counteracting contractile forces. Each slice contained ~98% parenchyma tissue; hence, all airways situated on a slice had sufficient parenchymal tissue to impart basal tone. Adjacent
slices containing contiguous segments of the same airway were paired and served as controls and were incubated at 37°C in a humidified air-CO₂ (95-5%) incubator. Sections were placed in fresh media every 2-3 hr during the remainder of day 1 and all of day 2 to remove agarose and endogenous substances released that variably confound the production of inflammatory mediators and/or alter airway tone.

**Precision cut lung slice bronchoconstriction measurements**- To assess luminal area, lung slices were placed in a 12-well plate in media and held in place using a platinum weight with nylon attachments. The airway was located using a microscope (Nikon Eclipse; model no. TE2000-U; magnification, ×40) connected to a live video feed (Evolution QEI; model no. 32-0074A-130 video recorder). Airway luminal area was measured using Image-Pro Plus software (version 6.0; Media Cybernetics) and represented in units of square micrometers (Cooper and Panettieri, 2008; Cooper et al., 2011). After functional studies, the area of each airway at baseline and for each dose of agonist was calculated using Image-Pro Plus software.

Lung slices were pretreated with FR900359 (0.1 or 1 μM), P4pal-10 (20 μM) or P4pal-10 Scr (20 μM) for 30 min at 37°C. Slices were then bronchoconstricted to a dose response of carbachol or histamine (10⁻⁸ – 10⁻⁴ M). Luminal area was measured and sigmoidal dose response curves generated from the data. Maximal bronchoconstriction (E_max), sensitivity of the airways to contractile agonist - log of the effective concentration to induce 50% bronchoconstriction (Log EC₅₀), and the integrated response to contractile agonist – area under the curve were calculated from the dose response curves generated and compared.

**Magnetic twisting cytometry**- Dynamic changes in cell stiffness were measured in isolated human ASM using forced motions of functionalized beads anchored to the cytoskeleton through cell surface integrin receptors, as described in detail previously (Fabry et al., 2001; An et al.,
The increase or decrease in stiffness is considered an index of single-cell smooth muscle contraction and relaxation, respectively. For these studies, serum-deprived, post-confluent cultured ASM cells were plated at 30,000 cells/cm² on plastic wells (96-well Removawell, Immulon II, Dynetech) previously coated with type I collagen (VitroCol; Advanced BioMatrix, Inc.) at 500 ng/cm², and maintained in serum-free media for 24 h at 37°C in humidified air containing 5% CO₂. These conditions have been optimized for seeding cultured cells on collagen matrix and for assessing their mechanical properties (Fabry et al., 2001; An et al., 2006; Deshpande et al., 2010). For each individual cell, baseline stiffness was measured for the first 60 sec and after drug addition stiffness was measured continuously for the next 240 sec; drug-induced changes in cell stiffness approached a steady-state level by 240 sec. Unless otherwise stated, ASM cells were pre-treated for 5 min with 3 μM pepducin. The effects of inhibitors were normalized to respective steady-state drug effects (without inhibitors).

Results

**P4pal-10 is an antagonist of multiple G₉-coupled receptors.** P4pal-10 is a ten amino acid pepducin derived from the third intracellular loop of PAR4 and was previously shown to inhibit G₉-signaling from PAR4, PAR1 and the TXA₂R (Covic et al., 2002; Stampfuss et al., 2003). To assess whether P4pal-10 broadly inhibits G₉ signaling, we monitored agonist-promoted calcium mobilization from endogenous GPCRs in HEK293 cells and in primary human ASM cells. P4pal-10 effectively inhibits responsiveness to a number of agonists including carbachol, bradykinin, histamine and ATP, with potencies that range from 0.24 μM (bradykinin) to 7.4 μM (ATP) (Fig. 1A & B). To examine if P4pal-10 was specific for G₉-coupled GPCRs, the ability to inhibit G protein activation from the β₂AR (Gₛ-coupled) and CXCR4 (Gᵢ-coupled) was also
assessed. P4pal-10 was unable to modulate cAMP production from the β₂AR (Fig. 1C) or adenylyl cyclase inhibition from CXCR4 (Fig. 1D). Thus, it appears that P4pal-10 operates through a specific subset of G_q-coupled receptors and does not act as a broad antagonist for G protein-receptor coupling.

**P4pal-10 inhibits cognate G protein coupling to PAR1 while FR900359 directly inhibits G_q activation.** It is plausible that P4pal-10 could operate by selectively inhibiting G_q activation in a receptor-dependent manner or by directly inhibiting activation of G_q. To dissect these potential mechanisms of action, the ability to modulate spontaneous nucleotide exchange was assessed using purified Gα_q. P4pal-10 had little effect on the rate of nucleotide exchange of Gα_q suggesting that it does not operate by directly restraining G_q dynamics (Fig. 2A). We also evaluated the effects of the G_q inhibitor FR900359 and, as expected, FR900359 effectively inhibits GTPγS incorporation and corroborates the similarities with YM-254890.

PAR1 is a protease-activated receptor that, when stimulated by thrombin or an exogenous peptide ligand, couples to G_q, G_i and G_{12/13} (Fig. 2B) (Gilchrist et al., 2001). As PAR1 couples to multiple G proteins and is sensitive to P4pal-10 (Fig. 1A), it serves as a good model to further dissect the mechanism of P4pal-10 inhibition. In a receptor-dependent model, P4pal-10 might operate by selectively inhibiting G_q coupling to PAR1 or by inhibiting cognate G_q, G_i and G_{12/13} coupling to PAR1. To study the ability of P4pal-10 and FR900359 in isolation, the cognate signaling from each G protein subtype was assessed in cells. Both FR900359 and P4pal-10 can inhibit PAR1-agonist peptide (PAR1-AP) stimulated calcium mobilization, an event typically associated with G_q activation (Fig. 2C). Activation of G_i decreases cAMP production due to inhibition of adenylyl cyclase activity (Bokoch et al., 1984). PAR1-mediated G_i coupling resulted in an ~40% decrease in forskolin-stimulated cAMP production. Cells pretreated with
P4pal-10 were unable to modulate forskolin-stimulated cAMP production similarly to cells pretreated with pertussis toxin, a well-characterized inhibitor of G\(_i\) activation (Fig. 2D). The scrambled control pepducin had no effect on adenylyl cyclase inhibition while FR900359 also did not alter G\(_i\) function, as it is a G\(_q\) specific inhibitor (Fig. 2D). PAR1 also couples to G\(_{12/13}\) activity that can be monitored through the detection of activated RhoA (McLaughlin et al., 2005). When active, RhoA binds GTP and undergoes a conformational change that can be detected by binding to a Rhotekin Rho Binding Domain glutathione-S-transferase fusion protein (GST-RBD). Using this assay, PAR1-AP effectively stimulated RhoA activation in HEK293 cells (Fig. 2E). Cells pretreated with P4pal-10 demonstrated a significant loss of detectable GTP-RhoA that was not observed in cells treated with FR900359 or P4pal-10 Scr (Fig. 2E). Using PAR1 as a model receptor, it appears that P4pal-10 may operate by inhibiting all cognate G protein coupling to a sensitive receptor such as PAR1, while FR900359 effectively inhibits G\(_q\) activation but does not alter receptor-stimulated activation of G\(_i\) or G\(_{12/13}\).

**Inhibition of G\(_q\)-activation by P4pal-10 or FR900359 effectively prevents synergistic airway smooth muscle growth.** Pathophysiologic advancement of chronic asthma includes the physical occlusion of the airway lumen by remodeling mechanisms such as ASM hyperplasia/hypertrophy (Al-Muhsen et al., 2011). *In vitro* models of ASM growth using isolated primary human ASM cells have established a synergistic relationship between the growth effects of receptor tyrosine kinase ligands, such as EGF and platelet-derived growth factor, and concurrent exposure to G\(_q\)-coupled receptor ligands (Ediger and Toews, 2000; Krymskaya et al., 2000; Gosens et al., 2003; Billington et al., 2005; Kong et al., 2006). Synergistic ASM cell growth is dependent on the activation of G\(_q\)-coupled GPCRs and operates independently of G\(_i\) activation (insensitive to pertussis toxin) and G\(_{12/13}\) signaling (insensitive to p115RhoGEF-
mediated G\textsubscript{12/13} inactivation) (Kong et al., 2006). As G\textsubscript{q} plays a central role in this phenomenon, it is plausible that the inhibition of G\textsubscript{q} activation could decouple the synergistic growth response from typical responsiveness to receptor tyrosine kinase-dependent growth factors. To examine this, primary human ASM cells were growth-arrested and exposed to thrombin (1 U/mL), epidermal growth factor (EGF, 10 nM) or co-treatment (thrombin + EGF) in the presence or absence of P4pal-10 or FR900359. As expected, ASM cells showed modest growth when treated with thrombin; more pronounced growth in the presence of EGF; and synergistic growth when co-treated with thrombin and EGF (Fig. 3A). FR900359 effectively inhibited the synergistic growth effect of thrombin + EGF treatment to levels comparable to EGF stimulation alone while cellular responsiveness to EGF was unaltered. P4pal-10 mirrored the pharmacological profile of FR900359 while P4pal-10 Scr had no effect on ASM growth (Fig. 3A).

The activation of G\textsubscript{q}-coupled GPCRs leads to the activation of myriad intracellular signaling pathways that can contribute to cell growth. Interestingly, the synergy between G\textsubscript{q}-coupled receptor agonists operates primarily through G\textsubscript{βγ}-dependent activation of Akt and downstream targets of Akt, particularly P70 S6 kinase (P70S6K) (Ediger and Toews, 2000; Krymskaya et al., 2000; Kong et al., 2006). Inhibition of src, Rho and Rho kinase along with knockdown of β-arrestin suggests no role for these signaling pathways in synergistic ASM growth (Kong et al., 2006). G\textsubscript{βγ} promotes AKT activation by direct phosphatidylinositol-3-kinase (PI3K) recruitment, phosphoinositol-dependent kinase-1 (PDK1) activation, and AKT-T308 phosphorylation by PDK1 (Billington et al., 2005). As for G\textsubscript{αq}, the signaling cascade that activates AKT is not as well established in ASM. Similar to the phenotypic growth assays, growth-arrested primary human ASM cells were treated, in the presence or absence of P4pal-10 or FR900359, with thrombin (1 U/mL), EGF (10 nM) or thrombin and EGF. Using an AKT
phosphospecific antibody detecting phosphorylation at S473, an indicator of activation, cells exhibited synergistic phosphorylation at S473 when co-stimulated with thrombin and EGF (Fig. 3B). Both FR900359 and P4pal-10 effectively inhibited synergistic responsiveness to levels comparable to cells treated with EGF alone. P4pal-10 Scr had little effect on agonist-promoted AKT phosphorylation (Fig. 3B).

**FR900359, but not P4pal-10, can interdict bronchoconstriction in human precision cut lung slices.** Airway hyperresponsiveness and amplified ASM shortening define the asthmatic diathesis. ASM contraction is mediated through myosin light chain phosphorylation downstream of G<sub>q</sub> activation (Hakonarson and Grunstein, 1998). Parasympathetic stimulation of airway contraction is primarily mediated through the M<sub>3</sub> muscarinic acetylcholine receptor (Canning and Fischer, 2001). However, it is known that activation of multiple G<sub>q</sub>-coupled GPCRs, including PARs and histamine receptors, can feed into the dynamics of airway contraction (Deshpande and Penn, 2006). Current therapeutic approaches may include the use of muscarinic or leukotriene receptor antagonists to attenuate the relative contribution of these receptors to the contractile state (Bel, 2013). Conceivably, due to the heterologous nature of the signaling inputs that regulate airway contraction, a molecule that inhibits multiple G<sub>q</sub>-coupled receptors, such as P4pal-10, or a molecule that directly inhibits G<sub>q</sub> activation, such as FR900359, may offer unique therapeutic benefits.

P4pal-10 and FR900359 inhibited the activation of G<sub>q</sub>-dependent processes such as calcium mobilization or synergistic ASM growth. However, these assays were performed with either suspended cells or ASM cells grown in monolayer. As ASM in situ is situated under a layer of epithelial cells in the airway, the therapeutic potential of P4pal-10 and FR900359 in the context of a bronchial tissue was studied using human precision cut lung slices. As an *ex vivo* model of
airway dynamics, precision cut lung slices remain responsive to multiple receptor agonists and have been used to study physiological processes including airway bronchoconstriction. Preincubation with 100 nM or 1 μM FR900359 shifted the EC$_{50}$ of carbachol-promoted airway contraction by 2- or 11-fold, respectively, and promoted a large reduction in maximal bronchoconstriction at 1 μM FR900359 (Fig. 4A & C) while P4pal-10 was ineffective at modulating contractile responsiveness to carbachol stimulation (Fig. 4B & C). Airway contraction was also assessed in response to histamine. As expected, FR900359 was able to effectively inhibit contractile responsiveness to high concentrations of histamine with EC$_{50}$ shifts >50-fold and a large reduction in maximal bronchoconstriction (Fig. 4D & F). Interestingly, P4pal-10 shifted the EC$_{50}$ of histamine responsiveness by 8-fold, albeit with a minimal effect on maximal bronchoconstriction, while P4pal-10 Scr had little effect on the EC$_{50}$ (Fig. 4E & F).

While it is expected that P4pal-10 would have the properties to interdict carbachol and histamine-promoted airway contraction, we observed relatively weak inhibition of these processes as compared to FR900359 (Fig. 4C & E). In the airway, the smooth muscle is situated under a layer of epithelial cells that P4pal-10 would have to bypass or transverse to access the ASM.

To more directly assess the ability of P4pal-10 to inhibit isolated ASM cell contraction, magnetic twisting cytometry was used to assay single cell contraction. P4pal-10 effectively inhibited carbachol and histamine-promoted single cell ASM contraction while having no effect on isoproterenol-promoted relaxation (Fig. 4F-H). Additionally, P4pal-10 Scr did not exhibit any significant effects on agonist-promoted single cell contraction or relaxation (Fig. 4F-H). As P4pal-10 was able to inhibit agonist-promoted contraction in isolated ASM cells but did not
exhibit similar efficacy in the PCLS model, tissue accessibility may be limiting the therapeutic efficacy of P4pal-10 in the airway.

**Discussion**

Asthma, a complex airway syndrome, manifests as airway hyperresponsiveness and inflammation due to multiple environmental and signaling inputs resulting in the exclusion of the airway lumen. $G_q$ plays a central role in the pathophysiology of airway disease and mediates ASM contractility, airway remodeling and ASM cell growth (Deshpande and Penn, 2006). To assess the effects of broadly inhibiting $G_q$ activation, we examined a receptor-dependent pepducin antagonist of $G_q$-activation alongside a small-molecule, direct inhibitor of $G_q$ activation.

P4pal-10 is a pepducin antagonist derived from intracellular loop 3 of PAR4. In the initial report, P4pal-10 exhibited strong inhibition of PAR4-mediated platelet aggregation with an IC$_{50}$ of ~ 0.5-1 μM and, interestingly, was able to also modulate PAR1-mediated platelet aggregation (Covic et al., 2002). P4pal-10 could also inhibit $G_q$-signaling in response to TXA$_2$R stimulation (Stampfuss et al., 2003), although this effect was not observed by Covic et al (Covic et al., 2002). By monitoring calcium mobilization in HEK293 and human ASM cells, P4pal-10 inhibited a number of $G_q$-coupled receptors with IC$_{50s}$ ranging from 0.24-7.4 μM. As the efficacy of P4pal-10 varied greatly depending on the agonist specificity, it seems unlikely that P4pal-10 is directly sequestering $G_q$ and preventing receptor interaction. Indeed, P4pal-10 did not modulate nucleotide exchange using purified $G_{α_q}$. An interesting property exhibited by P4pal-10 concerns the ability to interdict all G protein coupling to a single receptor. PAR1 can couple to $G_q$, $G_i$ and $G_{12/13}$, all of which can be inhibited by P4pal-10. It is unknown, at this time,
if P4pal-10 operates by restricting conformational dynamics of its targeted receptors to stabilize an inactive state or if P4pal-10 prevents receptor interaction with a G protein.

As P4pal-10 appears to operate through the receptor, the mechanism in which P4pal-10 inhibits a diverse set of G<sub>q</sub>-coupled receptors remains elusive. It was previously believed that pepducins operate through the cognate receptor from which they were derived (O’Callaghan et al., 2012); however, some pepducins, including P4pal-10, exhibit efficacy across multiple receptor subtypes (Stampfuss et al., 2003, Carr III et al., 2014). While many of these receptors do not share significant sequence similarity, many of the P4pal-10 sensitive receptors share strong, sequential homology with the N-terminal-half of the P4pal-10 sequence (SGRRYG). Some receptors that were characterized as P4pal-10 insensitive, such as the β2AR, may share some sequence homology with P4pal-10 but these regions of similarity are either short and highly disjointed or found in receptor regions that are likely not playing a role in P4pal-10 function (extracellular loops and transmembrane domains). Further, P4pal-10 sensitive receptors exhibited sequence homology with P4pal-10 in the intracellular domains of the receptor along with some portions of transmembrane domains that border the intracellular surface. With this in mind, P4pal-10 may interrupt critical intra-receptor or receptor-G protein contacts that are necessary for agonist-promoted G protein activation. As each receptor has distinct differences in receptor sequence, the spectrum of P4pal-10 sensitivity (Fig. 1A & B) may be attributed to the degree of similarity between the receptor and P4pal-10 or the unknown P4pal-10 interaction site.

FR900359, also known as UBO-QIC, was first reported as a methanol-extracted natural compound isolated from Ardisia crenata sims that was proposed to inhibit in vitro platelet aggregation and decrease blood pressure in rats (Fujioka et al., 1988). Similar to the well-studied YM-254890, FR900359 directly inhibited in vitro spontaneous nucleotide exchange using
purified $\alpha_q$ which suggests that it is operating by constraining $G_q$ conformational dynamics. Our studies confirmed the proposed specificity of the compound at concentrations ten-times higher than concentrations previously studied in vitro. FR900359 did not modulate $G_\alpha$, $G_i$, or $G_{12/13}$ signaling while strongly inhibiting $G_q$ activation (Inamdar et al, 2015). As many GPCRs couple to multiple $G$ proteins, the use of an inhibitor with defined specificity can effectively bias signaling from a GPCR. Most often studied is the ability of a GPCR agonist to promote a biased signal but FR900359 promotes an inhibitor-biased signal by selectively eliminating the activation of a particular intracellular signaling protein. Using PAR1, for example, FR900359 effectively eliminated $G_q$ activation from PAR1 while allowing activation of $G_i$ and $G_{12/13}$ from the same receptor. Thus, FR900359 changed PAR1 signaling from $G_q$, $G_i$ and $G_{12/13}$ to only $G_i$ and $G_{12/13}$. The concept of inhibitor biased signaling can be applied to a number of kinase inhibitors (e.g., $G$ protein-coupled receptor kinase (GRK), PKA, PKC, etc) or molecular inhibitors (pertussis toxin, Rho inhibitors, etc.) to modulate the lifetime (kinetics) or efficacy of signaling and, thus, provide a new dimension to biasing intracellular signaling pathways.

Investigation into the molecular mechanisms of airway disease clearly demonstrates a central role for $G_q$ activation and downstream signaling. Most prominently in patients with asthma, hyperresponsiveness of ASM by phosphorylation of myosin light chain is, in part, a downstream consequence of $G_q$-promoted calcium mobilization (Hakonarson and Grunstein, 1998). Although the mechanism of elevated $G_q$-signaling remains incompletely understood, it is believed that increased parasympathetic activation of the airway along with a local increase in $G_q$-coupled receptor agonists (e.g., thrombin, histamine, ATP) enhances contractile state of an asthmatic airway. It is suspected that both inputs contribute to the pathology as muscarinic antagonists only partially alleviate airway tension in patients (Bel, 2013). Using ex vivo human precision cut lung
slices, direct inhibition of G_q activation by FR900359 was able to significantly impact airway contraction. Thus, it is conceivable that the use of a G_q specific inhibitor may be an advantageous approach to the complex nature of treating bronchoconstriction in the asthmatic airway.

G_q also contributes to airway remodeling, including ASM growth, that physically occlude the lumen of the airway (Al-Muhsen, 2011). ASM proliferation is exacerbated in the disease state due to multiple factors including the increased presence of G_q-coupled receptor agonists such as histamine, acetylcholine, thromboxane, leukotriene D4, serotonin and ATP in the airway (Deshpande and Penn, 2006). In vitro models of ASM growth have established a synergistic relationship between the growth effects of receptor tyrosine kinase ligands, such as EGF and platelet-derived growth factor, and concurrent exposure to G_q-coupled receptor ligands that is mediated through the activation of Akt and P70S6K (Ediger and Toews, 2000; Krymskaya et al., 2000; Kong et al., 2006). Both P4pal-10 and FR900359 inhibited synergistic ASM growth and synergistic AKT activation with similar efficacy. These compounds, through fundamentally different mechanisms, inhibit synergy without modulating cellular responsiveness to a RTK growth factor further corroborates the critical role G_q plays in this phenomena and pathology. G_q can also promote the release of inflammatory factors such as cytokines (Fujii et al., 1998; Fujii and Kawashima, 2000). Considering the data monitoring ASM contractility and growth, it would be expected that both P4pal-10 and FR900359 may have a significant impact on the efficacy of this process.

To date, the in vivo efficacy of pepducins has been limited to treating diseases in which the target cell type is readily accessible. For example, PAR1- and PAR4-targeted pepducin antagonists were demonstrated to have significant efficacy in interdicting platelet thrombosis in mouse and non-human primate disease models (Covic et al., 2002; Zhang et al., 2012). In nude
mice, P1pal-7 effectively inhibited epithelial-derived lung tumor formation comparably to the current therapeutic standard Bevacizumab (Cisowski et al., 2011). A CXCR2 pepducin antagonist inhibited inflammation and spontaneous tumor development by inhibition of CXCR2-rich leukocyte association in an invasive intestinal adenocarcinoma murine model (Jamieson et al., 2012). It should be noted that each of the targeted cell types, such as platelets and leukocytes, were primarily accessible to circulating pepducins. In a tissue, the target cell types will likely need to have a surface accessible to the bloodstream in order for pepducin delivery. As pepducins do not have a particular targeting mechanism, the hydrophobic N-terminal palmitoyl group will likely incorporate into any membrane that it comes in contact with. In a multilayered tissue, the outermost cell type, epithelial cells in the case of the airway, may act as a sink to capture much of the available pepducin. This hypothesis is corroborated by the phenomena observed while monitoring ASM signaling pathways and contraction in cell monolayer in comparison to airway contraction in an ex vivo, intact airway using precision cut lung slices. P4pal-10 was unable to modulate airway contraction in the airway tissue but exhibited strong efficacy in inhibiting single cell contraction using isolated ASM cells. Additionally, P4pal-10 could inhibit Gq-dependent signaling in cell suspension or monolayer. Plausibly, as the ASM is situated under an epithelial layer, P4pal-10 cannot adequately penetrate the tissue to reach the ASM. In contrast, FR900359 significantly inhibited agonist-promoted contraction in the precision cut lung slices. These observations are likely a commentary on the current therapeutic limitations of the use of pepducins to treat human disease. As previously demonstrated, pepducins can offer novel therapeutic approaches if the targeted cell type is not part of a multilayered tissue (i.e., platelets, leukocytes) or it is able to interact with bioavailable pepducin (i.e., lung epithelial tissue). Beyond therapeutic application, it is becoming increasingly clear that
peptucins, including P4pal-10, can provide unique pharmacological tools and profiles that are not currently ascertainable using orthosteric ligands.
Acknowledgements

The authors would like to thank Drs. Christopher So, Thomas Charpentier, Raymond Penn and Matthew Schiewer for valuable discussions and Christopher Fischer and Dr. Philip Wedegaertner for their advice in generating the GST-RBD beads.

Author Contributions

Participated in research design: Carr III, Koziol-White, Lam, An, Panettieri and Benovic.

Conducted experiments: Carr III, Koziol-White, Lam and Zhang.

Contributed new reagents or analytic tools: Carr III, Koziol-White, Panettieri, Tall and An

Performed data analysis: Carr III, Koziol-White, Panettieri and Benovic

Wrote or contributed to the writing of the manuscript: Carr III, Koziol-White, An, Panettieri, Tall, and Benovic
References


Moulton BC, and Fryer AD (2011) Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. *Br J Pharmacol* 163: 44-52.


*Footnotes*

This research was supported by the National Institutes of Health National Institute of General Medical Sciences [Grants R37-GM047417, R01-GM068857, R01-GM088242, T32-GM100836], National Institutes of Health National Heart, Lung and Blood Institute [P01-HL114471, R01 HL107361] and National Institutes of Health National Institute of Environmental Health Sciences [P30-ES013508].
Figure Legends

**Fig. 1.** P4pal-10 is an antagonist of multiple G_q-coupled receptors. (A) Agonist-promoted calcium mobilization was monitored by Fura-2AM fluorescence in HEK293 and HASM cells pretreated for 1 min with various concentrations of P4pal-10. Peak fluorescence values are reported. (B) P4pal-10 IC_{50} values are reported for responsiveness to various G_q-coupled receptor agonists. (C) 10 μM P4pal-10 does not inhibit isoproterenol-stimulated cAMP production (G_s-mediated) in HEK293 cells. The data are represented by the mean ± SD from three independent experiments. ns- not significant **- p< 0.01 versus forskolin-treated cells using a two-way unpaired t-test.

**Fig. 2.** P4pal-10 inhibits cognate G protein coupling to PAR1 while FR900359 directly inhibits G_q. (A) 100 nM FR900359, but not 10 μM P4pal-10, interdicts spontaneous GTPγS binding to purified Gα_q. The data are represented by the mean ± SD from three independent experiments. (B) PAR1 can couple to G_q (measured by calcium mobilization), G_i (measured by adenylyl cyclase inhibition) and G_{12/13} (measured by RhoA activation). (C) 10 μM P4pal-10 and 100 nM FR900359 inhibits PAR1-AP promoted calcium mobilization. ***- p< 0.001 versus vehicle-treated cells using a two-way unpaired t-test. (D) 10 μM P4pal-10, but not 100 nM FR900359 or 10 μM P4pal-10 Scr, can inhibit PAR1-dependent G_i activation. P4pal-10 exhibited comparable efficacy to pertussis toxin, an inhibitor of G_i activation. The data are represented by the mean ± SD from three independent experiments. ns- not significant, **- p< 0.01 and ***- p< 0.001 versus PAR1-AP-treated cells using a two-way unpaired t-test. (E) 10 μM P4pal-10, but not 100 nM FR900359 or 10 μM P4pal-10 Scr, can inhibit PAR1-AP stimulated G_{12/13} activation. The
data are represented by the mean ± SD from three independent experiments. ns- not significant, ***- p< 0.001 versus PAR1-AP-treated cells using a two-way unpaired t-test.

**Fig. 3.** Inhibition of G_q-activation by P4pal-10 or FR900359 effectively inhibits synergistic HASM growth and growth signaling. (A) 10 μM P4pal-10 or 100 nM FR900359, but not P4pal-10 Scr, can significantly inhibit synergistic human ASM growth in response to EGF and thrombin co-treatment while not modulating EGF-promoted cell growth. Cell growth was monitored 24 hr post-stimulation using a PicoGreen fluorescence assay. The data are represented by the mean ± SD of three independent experiments. ***- p< 0.001 versus vehicle-treated cells using a two-way unpaired t-test. (B) 10 μM P4pal-10 or 100 nM FR900359, but not P4pal-10 Scr, can significantly inhibit synergistic Akt phosphorylation at S473 in response to EGF and thrombin co-treatment while not modulating EGF-promoted phosphorylation. AKT-S473 phosphorylation was assessed by western blot six hr post-stimulation. The data are represented by the mean ± SD of three independent experiments. ns-not significant, **- p< 0.01 versus vehicle-treated cells incubated with thrombin and EGF using a two-way unpaired t-test.

**Fig. 4.** FR900359, but not P4pal-10, can inhibit airway contraction in human precision cut lung slices. (A) 100 nM and 1 μM FR900359 inhibited carbachol-promoted airway contraction. The data are represented by the mean ± SEM of four independent experiments and fitted to a sigmoidal dose-response model. (B) P4pal-10 and P4pal-10 Scr had no effect on airway contraction in response to carbachol. The data are represented by the mean ± SEM of four independent experiments and fitted to a sigmoidal dose-response model. The “no inhibitor” curve is derived from the same data set in both panel A and B. (C) 100 nM or 1 μM FR900359
shifted the estimated EC₅₀ value of carbachol-promoted airway contraction by 2- and 11-fold, respectively. P4pal-10 and P4pal-10 Scr did not modulate carbachol responsiveness. The data are represented by the mean ± SEM of four independent experiments. ns-not significant, ***- p< 0.001 versus vehicle-treated tissue using a two-way unpaired t-test. (D) 100 nM and 1 μM FR900359 effectively inhibited histamine-promoted airway contraction. The data are represented by the mean ± SEM of three independent experiments and fitted to a sigmoidal dose-response model. (E) P4pal-10 partially inhibited airway contraction in response to histamine. The data are represented by the mean ± SEM of three independent experiments and fitted to a sigmoidal dose-response model. The “no inhibitor” curve is derived from the same data set in both panel D and E. (F) P4pal-10 shifted the estimated EC₅₀ value of histamine-promoted airway contraction by 8-fold while 100 nM and 1 μM FR900359 shifted the EC₅₀ >50-fold. The data are represented by the mean ± SEM of three independent experiments. ns-not significant, *- p< 0.05, **- p< 0.01 versus vehicle-treated tissue using a two-way unpaired t-test. (G) Magnetic twisting cytometry analysis of isolated ASM dynamics shows that pretreatment with 3 μM P4pal-10 (n=232) significantly inhibited carbachol-promoted single-cell contraction as compared to “no inhibitor”/vehicle treatment (n=331). P4pal-10 Scr did not exhibit similar efficacy (n=266). The data sets are normalized to “no inhibitor”/vehicle treatment. ns-not significant, ***- p< 0.001 compared to vehicle-treated cells using a one-way ANOVA analysis. (H) Magnetic twisting cytometry analysis of isolated ASM dynamics shows that pretreatment with 3 μM P4pal-10 (n=867) significantly inhibited histamine-promoted single-cell contraction as compared to “no inhibitor”/vehicle treatment (n=692). P4pal-10 Scr did not exhibit similar efficacy (n=486). The data sets are normalized to “no inhibitor”/vehicle treatment. ns-not significant, ***- p< 0.001 compared to vehicle-treated cells using a one-way ANOVA analysis. (I) Magnetic twisting
cytometry analysis of isolated ASM dynamics shows that pretreatment with 3 μM P4pal-10 (n=418) or P4pal-10 Scr (n=292) did not modulate isoproterenol-promoted single-cell relaxation as compared to “no inhibitor”/vehicle treatment (n=569). The data sets are normalized to “no inhibitor”/vehicle treatment. ns-not significant compared to vehicle-treated cells using a one-way ANOVA analysis.
**Figure 1**

A) Graph showing the relationship between log[P4pal-10], M and % Response, Ca^{2+} mobilization.

B) Table of agonists, receptors, IC_{50} values, and cell types.

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Receptor</th>
<th>IC_{50} (μM)</th>
<th>Cell Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bradykinin</td>
<td>Bradykinin B2</td>
<td>0.24 ± 0.03</td>
<td>HASM</td>
</tr>
<tr>
<td>Carbachol</td>
<td>M3 Muscarinic</td>
<td>0.66 ± 0.05</td>
<td>HEK293</td>
</tr>
<tr>
<td>PAR1-AP</td>
<td>PAR1</td>
<td>4.10 ± 0.30</td>
<td>HEK293</td>
</tr>
<tr>
<td>Histamine</td>
<td>Histamine H1</td>
<td>5.87 ± 0.63</td>
<td>HASM</td>
</tr>
<tr>
<td>ATP</td>
<td>P2Y_{1/2}</td>
<td>7.36 ± 0.39</td>
<td>HEK293</td>
</tr>
</tbody>
</table>

C) Bar graph showing % cAMP production (10 min, normalized to isoproterenol). No significant difference (ns).

D) Bar graph showing % forskolin response, cAMP. Significant differences denoted by **. 
Figure 4

(A) Bronchoconstriction (%) vs. Log[Carbachol], M
- No Inhibitor
- 100 nM FR900359
- 1 µM FR900359

(B) Bronchoconstriction (%) vs. Log[Carbachol], M
- No Inhibitor
- P4pal-10
- P4pal-10 Scr

(C) Fold change EC50
- No Inhibitor
- 100 nM FR900359
- 1 µM FR900359
- P4pal-10
- P4pal-10 Scr

(D) Bronchoconstriction (%) vs. Log[Histamine], M
- No Inhibitor
- 100 nM FR900359
- 1 µM FR900359

(E) Bronchoconstriction (%) vs. Log[Histamine], M
- No Inhibitor
- P4pal-10
- P4pal-10 Scr

(F) Fold change EC50
- No Inhibitor
- 100 nM FR900359
- 1 µM FR900359
- P4pal-10
- P4pal-10 Scr

(G) Normalized Single-Cell Contraction, %
- No Inhibitor
- P4pal-10
- P4pal-10 Scr

(H) Normalized Single-Cell Contraction, %
- No Inhibitor
- P4pal-10
- P4pal-10 Scr

(I) Normalized Single-Cell Relaxation, %
- No Inhibitor
- P4pal-10
- P4pal-10 Scr